On the evening of January 11, Kehua Biotechnology (002022) announced that the company's largest shareholder, Zhuhai Baolian Investment Holdings, transferred 5% of the company's shares to Xi'an Grant Thornton Principal Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as Xi'an Grant Thornton), and the transfer was 20 yuan shares, with a transaction consideration of 51.4 billion yuan, at the same time, Zhuhai Baolian will hold the company 10The voting rights corresponding to 64% of the shares are freely, irrevocably and exclusively entrusted to Xi'an Grant Thornton.
At the same time, the two parties intend to cooperate in promoting the adjustment and re-election of the board of directors and the board of supervisors of Kehua Biotech, and the status of the company without controlling shareholders and actual controllers will change, and Peng Niancai, the actual controller of Xi'an Grant Thornton, will become the actual controller of Kehua Biotech.
Usher in a new actual controller
Kehua Biotech is a veteran listed company in the in vitro diagnostic industry, and after the equity transfer and voting rights entrustment, the company will usher in a new actual controller.
According to the announcement, the two parties to this transaction intend to cooperate with the promotion of the adjustment and re-election of the board of directors and the board of supervisors of Kehua Biotechnology, so as to achieve a total of 9 seats on the board of directors and 3 seats on the board of supervisors, Xi'an Grant Thornton nominated 5 non-independent directors and 2 shareholder supervisors, and recommended 3 independent director candidates, Zhuhai Baolian nominated 1 non-independent director, and 1 employee supervisor was democratically elected by the employee congress or employees.
According to public information, Peng Niancai is a professor and doctoral supervisor of Xi'an Jiaotong University, has presided over a number of national key scientific research projects, and has rich experience in the in vitro diagnostic industry.
In addition, they indirectly hold Xi'an Grant Thornton 654% and 4Li Ming and Miao Baogang, who have a 02% share, are professionals who have been focusing on molecular diagnostic testing for a long time and have rich experience in the in vitro diagnostic industry. After this transaction, the professional team in the in vitro diagnostic industry will take over Kehua Biotech, and the industrial synergy will be conducive to the development of listed companies in the industry.
It is worth noting that the transaction also involves another state-owned asset, and the announcement shows that the actual controller is Xi'an Investment Holdings, which is the Xi'an Municipal Bureau of Finance, holds a total of 38 Xi'an Grant Thornton Principal Benefit Enterprise Management Partnership (Limited Partnership).9% share.
In recent years, Xi'an aims to build a 100-billion-level biomedical industry cluster, and has formed a new industrial chain pattern based on chemical drugs, biological drugs, Chinese patent medicines, and medical device industries, led by high-precision technologies such as regenerative medicine, gene sequencing, peptides and proteins, with continuous expansion of industrial scale, continuous enhancement of innovation capabilities, gradual demonstration of enterprise vitality, and further optimization of spatial layout and industrial ecology.
Zhuhai state-owned assets optimize allocation
According to the content of the transaction, Zhuhai Baolian still holds 1364% of the shares of Kehua Biotechnology and 3% of the voting rights of the shares, during the voting rights entrustment period, Zhuhai Baolian and Xi'an Grant Thornton constitute concerted actors, are still important shareholders of Kehua Biotech, and will still share the dividends of Kehua Biotech's long-term growth.
Zhuhai Baolian is a wholly-owned subsidiary of Gree Real Estate, and on the evening of the same day, Gree Real Estate also made an announcement on the above transaction. Gree Real Estate said that the company's implementation of this transaction for its own strategic development and industrial optimization needs is conducive to further focusing on key development directions and optimizing resource allocation.
It is reported that in vitro diagnostic products refer to in vitro diagnostic reagents managed by medical devices, that is, products and services that obtain clinical diagnostic information through the detection of human samples (blood, body fluids, tissues, etc.) outside the human body, and then judge diseases or body functions.
In vitro diagnostics is one of the fastest-growing and most active sub-industries in the medical industry in recent years, and has gradually become a mature industry with significant scale around the world. China's in vitro diagnostic industry has experienced the stage of product introduction, independent production standard development stage, and has now entered the stage of rapid growth of the industry.
Industry insiders believe that through the introduction of a professional team, the listed company, Zhuhai state-owned assets and the new actual controller can all benefit, demonstrating the resource integration ability of local state-owned assets and truly giving full play to the empowerment of state-owned capital.
The domestic and international markets are working simultaneously
After years of development, Kehua's business has covered three major fields: molecular diagnosis, biochemical diagnosis and immunodiagnosis, and adheres to the common development strategy of "reagent + instrument", with more than 100 reagents and instrument products.
According to the "China Medical Device Blue Book 2021", Kehua Biotech ranks third in the industry in the molecular diagnosis market. According to the data of Kehua Biotech's 2023 semi-annual report, the company's products cover more than 12,000 terminal hospitals, more than 500 disease control centers, blood centers, blood banks, biomedical enterprises and scientific research institutes in more than 30 provinces, municipalities and autonomous regions across the country, and are exported to more than 100 countries and regions overseas.
At the end of 2023, Kehua Biotech participated in the centralized procurement of the inter-provincial alliance of renal function and cardiac enzyme biochemical detection reagents and the centralized procurement of the inter-provincial alliance of in vitro diagnostic reagents in 2023 in 25 provinces (autonomous regions and corps), and declared 21 projects in the biochemical capacity group and the test group, HPV-DNA typing detection, HCG (chemiluminescence method) and other groups of products were shortlisted for the winning bid.
A few days ago, Kehua Biotechnology said that Tianlong Company, a holding subsidiary of the company, produces and sells influenza A and B virus RNA detection kits (fluorescent PCR) for the detection of influenza A and B viruses, and Mycoplasma pneumoniae (MP) nucleic acid detection kits (fluorescent PCR method) for the detection of Mycoplasma pneumoniae.
In addition to actively embracing centralized procurement in the domestic market, in the recent institutional survey, Kehua Biotech said that it will take advantage of the sales network of TGS, an Italian holding subsidiary, in Europe to actively explore the market, take China and emerging market countries as the main growth driver, and at the same time increase the international market competitiveness of independent products, build brand awareness and influence, and accelerate global penetration through continuous cultivation in developed countries, according to the 2023 semi-annual report, Kehua Biotech's overseas market revenue accounts for 14%.
Recently, Kehua Biotech has frequently obtained the "Medical Device Registration Certificate" issued by the Food and Drug Administration, and this time it ushered in a new actual controller, coupled with the joining of senior teams in the industry and the continuous empowerment of state-owned assets, the future is promising. Kehua Biotech said that if the transaction is successfully implemented, it will contribute to the company's stable development in the future, help the company's healthy and sustainable development, and help improve the company's governance ability and anti-risk ability.